OncoMatch/Clinical Trials/NCT05512208
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
Is NCT05512208 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Avutometinib (VS-6766) + defactinib for endometrioid cancer.
Treatment: Avutometinib (VS-6766) + defactinib — The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or solid gynecological cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Ovarian Cancer
Cervical Cancer
Tumor Agnostic
Biomarker criteria
Required: KRAS mutation
mutated RAS
Required: NRAS mutation
mutated RAS
Required: HRAS mutation
mutated RAS
Required: BRAF type I mutation
BRAF (type I, II, and/or III)
Required: BRAF type II mutation
BRAF (type I, II, and/or III)
Required: BRAF type III mutation
BRAF (type I, II, and/or III)
Required: NF1 loss of function
NF-1 loss of function
Required: KRAS activation
RAS activation
Required: NRAS activation
RAS activation
Required: HRAS activation
RAS activation
Disease stage
Required: Stage FIGO STAGE II-IV (FIGO)
Metastatic disease required
metastatic disease (FIGO stage II-IV)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy — metastatic
Cannot have received: mek inhibitor
Cannot have received: raf inhibitor
Lab requirements
Blood counts
hemoglobin ≥9.0 g/dL; platelets ≥100,000/mm3; ANC ≥1500/mm3
Kidney function
creatinine clearance rate of ≥50 mL/min (Cockcroft-Gault) or serum creatinine ≤ 1.5 x ULN
Liver function
total bilirubin ≤1.5 × ULN (subjects with Gilbert syndrome may enroll if total bilirubin is <3.0 mg/dL); ALT and AST ≤2.5 × ULN (or <5x ULN in subjects with liver metastases)
Cardiac function
left ventricular ejection fraction ≥ 55% by ECHO or MUGA scan; baseline QTc interval < 460 ms (average of triplicate readings) (CTCAE Grade1) using Fredericia's QT correction formula
Must have adequate organ function defined by the following laboratory parameters: ... see protocol for full details
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- AdventHealth · Orlando, Florida
- Louisiana State University Medical Center New Orleans · New Orleans, Louisiana
- University of New Mexico Comprehensive Cancer Center · Albuquerque, New Mexico
- Stephenson Cancer Center · Oklahoma City, Oklahoma
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05512208 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior mek inhibitor, raf inhibitor disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS mutation is a required biomarker for enrollment.
Does this trial require NRAS?
Yes, NRAS mutation is a required biomarker for enrollment.
Does this trial require HRAS?
Yes, HRAS mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage FIGO STAGE II-IV is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 99 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages